CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 167 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,912,393 | -18.9% | 759,898 | 0.0% | 3.21% | -10.5% |
| Q2 2023 | $25,783,339 | -5.7% | 759,898 | 0.0% | 3.59% | -8.8% |
| Q1 2023 | $27,341,130 | -19.4% | 759,898 | -0.2% | 3.93% | -25.5% |
| Q4 2022 | $33,935,509 | +58.6% | 761,398 | 0.0% | 5.28% | +43.0% |
| Q3 2022 | $21,403,000 | +4.3% | 761,398 | 0.0% | 3.69% | -32.6% |
| Q2 2022 | $20,527,000 | -20.8% | 761,398 | 0.0% | 5.48% | -2.3% |
| Q1 2022 | $25,933,000 | -11.9% | 761,398 | 0.0% | 5.61% | -2.1% |
| Q4 2021 | $29,420,000 | -28.4% | 761,398 | 0.0% | 5.72% | -43.4% |
| Q3 2021 | $41,108,000 | +119.0% | 761,398 | +35.6% | 10.12% | +160.3% |
| Q2 2021 | $18,773,000 | +62.3% | 561,398 | 0.0% | 3.89% | -10.7% |
| Q1 2021 | $11,565,000 | -36.6% | 561,398 | -46.1% | 4.36% | -31.1% |
| Q4 2020 | $18,245,000 | – | 1,041,398 | – | 6.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |